OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company specializing in antibody discovery platforms, having entered the public markets in 2022 through a business combination with Avista Public Acquisition Corp. II, sponsored by Avista Capital Partners. The company, which was spun out of Ligand Pharmaceuticals as part of the de-SPAC transaction, provides transgenic animal and other technologies that enable partners to discover therapeutic antibody candidates across a range of disease areas. OmniAb filed an 8-K with the SEC on June 18, 2025, continuing its post-merger public reporting obligations as an active Nasdaq-listed issuer in the biotechnology sector. Sign up at SpacDesk for full filing history, sponsor analytics, and real-time SPAC data on OABI and hundreds of other de-SPAC companies.